Subjects -> MEDICAL SCIENCES (Total: 8185 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 151 of 151 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 2)
Acta Haematologica     Full-text available via subscription   (Followers: 23)
Acta Haematologica Polonica     Open Access  
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 52)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 15)
Archives of Hematology Case Reports and Reviews     Open Access  
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 29)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 4)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 297)
Blood Advances     Open Access   (Followers: 7)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 18)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 8)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 60)
Blood Pressure     Open Access  
Blood Pressure Monitoring     Hybrid Journal   (Followers: 1)
Blood Purification     Full-text available via subscription   (Followers: 6)
Blood Reviews     Hybrid Journal   (Followers: 26)
BMC Hematology     Open Access   (Followers: 7)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 29)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 17)
British Journal of Diabetes & Vascular Disease     Open Access   (Followers: 21)
British Journal of Haematology     Hybrid Journal   (Followers: 60)
British Journal of Primary Care Nursing - Cardiovascular Disease, Diabetes and Kidney Care     Full-text available via subscription   (Followers: 10)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 28)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 32)
Clinical Diabetes     Full-text available via subscription   (Followers: 39)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 20)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Clinical Lymphoma Myeloma and Leukemia     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Blood Disorders     Open Access   (Followers: 1)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 3)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 24)
Current Diabetes Reviews     Hybrid Journal   (Followers: 27)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 20)
Cytotherapy     Full-text available via subscription   (Followers: 2)
Der Diabetologe     Hybrid Journal   (Followers: 2)
Diabetes     Full-text available via subscription   (Followers: 411)
Diabetes aktuell     Hybrid Journal   (Followers: 3)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 20)
Diabetes Care     Full-text available via subscription   (Followers: 469)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 27)
Diabetes Management     Full-text available via subscription   (Followers: 15)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 70)
Diabetes Spectrum     Full-text available via subscription   (Followers: 16)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 50)
Diabetes Therapy     Open Access   (Followers: 23)
Diabetic Foot & Ankle     Open Access   (Followers: 10)
Diabetic Medicine     Hybrid Journal   (Followers: 148)
Diabetologia     Hybrid Journal   (Followers: 206)
Diabetologia Kliniczna     Hybrid Journal  
Diabetologie und Stoffwechsel     Hybrid Journal   (Followers: 2)
Egyptian Journal of Haematology     Open Access  
eJHaem     Open Access  
European Journal of Haematology     Hybrid Journal   (Followers: 16)
Experimental Hematology     Hybrid Journal   (Followers: 6)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 5)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Global Journal of Transfusion Medicine     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 33)
Haemophilia     Hybrid Journal   (Followers: 66)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematología     Open Access  
Hematology     Open Access   (Followers: 15)
Hematology Reports     Open Access   (Followers: 4)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hematology/Oncology and Stem Cell Therapy     Open Access   (Followers: 6)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 1)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 2)
Info Diabetologie     Full-text available via subscription   (Followers: 1)
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access  
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 6)
International Journal of Diabetes Research     Open Access   (Followers: 8)
International Journal of Hematologic Oncology     Open Access   (Followers: 2)
International Journal of Hematology     Hybrid Journal   (Followers: 4)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Hematology-Oncology and Stem Cell Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 25)
Iraqi Journal of Hematology     Open Access  
JMIR Diabetes     Open Access  
Journal of Blood Disorders & Transfusion     Open Access   (Followers: 3)
Journal of Applied Hematology     Open Access   (Followers: 2)
Journal of Blood Medicine     Open Access   (Followers: 1)
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 20)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 25)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 8)
Journal of Diabetes Investigation     Open Access   (Followers: 12)
Journal of Diabetes Mellitus     Open Access   (Followers: 5)
Journal of Diabetes Research     Open Access   (Followers: 13)
Journal of Diabetes Research     Open Access   (Followers: 9)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology     Open Access   (Followers: 2)
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Hypo & Hyperglycemia     Partially Free  
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 8)
Journal of Social Health and Diabetes     Open Access   (Followers: 1)
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 81)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 35)
Journal of Transfusion Medicine     Full-text available via subscription  
Kidney and Blood Pressure Research     Open Access   (Followers: 4)
Leukemia     Hybrid Journal   (Followers: 22)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 12)
Leukemia Research     Hybrid Journal   (Followers: 8)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Mediterranean Journal of Hematology and Infectious Diseases     Open Access  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 20)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 8)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Platelets     Hybrid Journal   (Followers: 3)
Practical Diabetes     Hybrid Journal   (Followers: 7)
Primary Care Diabetes     Hybrid Journal   (Followers: 26)
Research & Reviews : Journal of Oncology and Hematology     Full-text available via subscription   (Followers: 1)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 1)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 12)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 45)
Thalassemia Reports     Open Access   (Followers: 1)
The Lancet Haematology     Full-text available via subscription   (Followers: 38)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 145)
Thrombosis Research     Hybrid Journal   (Followers: 47)
Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie     Hybrid Journal  
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 13)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Journal Cover
Clinical Lymphoma Myeloma and Leukemia
Number of Followers: 5  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 2152-2650 - ISSN (Online) 2152-2669
Published by Elsevier Homepage  [2906 journals]
  • Recent Advances in the Use of Chimeric Antigen Receptor–Expressing
           T-Cell Therapies for Treatment of Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Thomas Martin; Carolyn C. Jackson, Lida Pacaud, Deepu Madduri, Sundar Jagannath
      Abstract: Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized the treatment paradigm for heavily pretreated B-cell malignancies such as large B-cell lymphoma. There is a major unmet need for effective treatments for heavily pretreated relapsed/refractory multiple myeloma (RRMM), for which many CAR-T therapies are under active clinical investigation.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-09-19
      DOI: 10.1016/j.clml.2022.09.001
       
  • Dupilumab in Multiple Myeloma: A Case Series

    • Free pre-print version: Loading...

      Authors: Shayan Owji; Danielle Dubin, Daniel Yassky, Joseph Han, Kathryn Tan, Sundar Jagannath, Samir Parekh, Nicholas Gulati
      Abstract: T helper 2 (Th2)-derived cytokines, interleukin (IL)-4 and IL-13, are central in the regulation of the immune system response and microenvironment under normal physiological conditions; however, these proteins also play a vital role in disease states such as atopy and cancer.1,2,3 Increased activity of these pleiotropic effector cytokines has been closely associated with malignancy due to their roles in carcinogenesis and modulation of tumor immunosurveillance.3,4,5,6 In particular, IL-4 and IL-13 may directly stimulate tumor-associated macrophages and myeloid-derived suppressor cells, leading to unwanted tumor progression.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-09-19
      DOI: 10.1016/j.clml.2022.09.002
       
  • Allogeneic haematopoietic stem cell transplantation for
           relapsed/refractory acute myeloid leukaemia: A single-centre experience

    • Free pre-print version: Loading...

      Authors: Anna Kopińska; Patryk Węglarz, Anna Koclęga, Agata Wieczorkiewicz-Kabut, Krzysztof Woźniczka, Anna Armatys, Adrianna Spałek, Iwona Grygoruk-Wiśniowska, Sebastian Grosicki, Aleksandra Butrym, Jarosław Czyż, Agata Obara, Tomasz Gromek, Grzegorz Helbig
      Abstract: We present our single-centre data on the safety and efficacy of allogenic stem cell transplantation in the r/r AML. The retrospective analysis included 64 patients. Our results confirm that secondary AML and the number of pretransplantation treatment lines increased the risk of progression, cGVHD showed the opposite effect. We confirm that patients with r/r AML should be transplanted as soon as possible, even after the first unsatisfactory induction.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-09-07
      DOI: 10.1016/j.clml.2022.08.014
       
  • SF3B1, RUNX1 and TP53 mutations significantly impact the outcome of
           patients with lower-risk myelodysplastic syndrome.

    • Free pre-print version: Loading...

      Authors: Jose F Falantes; Francisco J Márquez-Malaver, Estrella Carrillo, Marta García Culebras, Rosario Morales, Concepción Prats, Maria T Vargas, Teresa Caballero, Eduardo Rodríguez-Arbolí, Ildefonso Espigado, Jose Antonio Pérez-Simón
      Abstract: Introduction: Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS including all risk categories. Recently, the incorporation of genomic data to clinical parameters defined the new Molecular International Prognostic Scoring System (IPSS-M). Materials and Methods: In this study, we evaluated the impact of molecular profile in a series of 181 patients with LR-MDS and non-proliferative chronic myelomonocytic leukemia.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-28
      DOI: 10.1016/j.clml.2022.08.012
       
  • Ixazomib with or without rituximab following maintenance autologous stem
           cell transplant in mantle cell lymphoma: A single-center phase 1 trial

    • Free pre-print version: Loading...

      Authors: Jason T. Romancik; Zhengjia Chen, Pamela B. Allen, Edmund K. Waller, Kelly Valla, Amanda Colbert, Cecilia Rosand, Alexandra F. Palmer, Christopher R. Flowers, Jonathon B. Cohen
      Abstract: : The authors conducted a phase 1 study investigating the use of ixazomib, an oral proteasome inhibitor, with or without rituximab in patients with mantle cell lymphoma in first remission following chemoimmunotherapy and autologous stem cell transplantation. All patients treated on study remain in complete remission with a median follow-up of 46 months, but the study was closed early due to a high rate of hematologic adverse events.Induction chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard first-line treatment for fit patients with mantle cell lymphoma (MCL).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-23
      DOI: 10.1016/j.clml.2022.08.013
       
  • SOHO State of the Art Updates and Next Questions
           

    • Free pre-print version: Loading...

      Authors: Ibrahim Aldoss; Hoda Pourhassan, Dan Douer
      Abstract: The adoption of pediatric-inspired regimens in young adults with newly diagnosed acute lymphoblastic leukemia (ALL) has significantly improved their survival outcomes. Pediatric-inspired regimens in ALL rely profoundly on delivering adequate dosing of non-myelosuppressive drugs of which asparaginase, a bacterial derived agent, is a key component. Asparaginase therapy is associated with a spectrum of unique toxicities that are observed more frequently in adult patients compared to children with ALL, and this observation has contributed to the reluctance of adult oncologists to administer the drug to their patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-23
      DOI: 10.1016/j.clml.2022.08.009
       
  • Thrombocytopenia in patients with myelofibrosis: a practical management
           guide

    • Free pre-print version: Loading...

      Authors: Douglas Tremblay; Ian Baine, John Mascarenhas
      Abstract: Patients with myelofibrosis (MF) frequently develop thrombocytopenia as a consequence of bone marrow fibrosis, splenic sequestration, and myelosuppression from an inflammatory microenvironmental milieu. Thrombocytopenia occurs frequently at diagnosis, worsens with disease progression, is an independent adverse prognostic factor, and limits effective dosing of JAK2 inhibitors. Recently, pacritinib was approved for patients with MF and extreme thrombocytopenia. However, this JAK2/IRAK1 inhibitor is not primarily used to attain improvement in platelet count.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-23
      DOI: 10.1016/j.clml.2022.08.011
       
  • Characteristics and outcomes of secondary acute myeloid leukemia and acute
           myeloid leukemia with myelodysplasia-related changes: Multicenter study
           from the Thai Acute Leukemia Study Group

    • Free pre-print version: Loading...

      Authors: Chantiya Chanswangphuwana; Chantana Polprasert, Weerapat Owattanapanich, Smith Kungwankiattichai, Adisak Tantiworawit, Thanawat Rattanathammethee, Wasithep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chinadol Wanitpongpun, Chajchawan Nakhakes, Kannadit Prayongratana, Chantrapa Sriswasdi
      Abstract: Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) both result in dismal outcomes. This retrospective study aimed to determine whether these features are poor prognostic factors independent of older age and adverse cytogenetics, which are commonly associated with a poor prognosis.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-22
      DOI: 10.1016/j.clml.2022.08.010
       
  • Response to “A Review and Update with Perspective of Evidence that the
           Herbicide Glyphosate (Roundup) is a Cause of Non-Hodgkin Lymphoma”

    • Free pre-print version: Loading...

      Authors: Robert E. Tarone
      Abstract: A recent perspective by Weisenburger1 falsely claims that my paper2 criticizing the International Agency for Research on Cancer (IARC) classification of glyphosate as a probable human carcinogen was “industry-sponsored”. Claims that I have an industry conflict of interest with regard to this paper, or any other publication on the IARC glyphosate classification, have previously been rebutted in detail.3 The paper was written without consultation with, or pay from, any entity associated with industry, and demonstrated that the glyphosate classification was erroneous, because of a seriously flawed summary of rodent tumor data.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-21
      DOI: 10.1016/j.clml.2022.08.007
       
  • An epidemiological model to estimate the prevalence of diffuse large
           B-cell lymphoma in the United States

    • Free pre-print version: Loading...

      Authors: Dai Chihara; Karissa Johnston, Talshyn Bolatova, Shelagh Szabo, Anupama Kalsekar, Alex Mutebi, Huiying Yang, Yangyang Liu, Dionna Attinson, Martin Hutchings
      Abstract: Prevalence is reflective of disease incidence and survival, and defined as the number of patients living with active disease. In diseases such as diffuse large B-cell lymphoma (DLBCL) with treatments with curative potential, a proportion of patients are cured, leading to a need for accurate, contemporary estimates of DLBCL prevalence to gauge the impact of the rapidly emerging treatment landscape.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-20
      DOI: 10.1016/j.clml.2022.08.008
       
  • The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell
           Lymphoma: A Meta-analysis and Systematic Literature Review

    • Free pre-print version: Loading...

      Authors: Peng-Peng Xu; Rong Shen, Zi-Yang Shi, Shu Cheng, Li Wang, Yang Liu, Lu Zhang, Ruiqi Huang, Xiaopeng Ma, Xikun Wu, Hui Yao, Yiling Yu, Wei-Li Zhao
      Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma 1, affecting approximately 40% of population globally. Although chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)2,3 is considered as a standard therapy for treatment of patients with DLBCL, the 5-year survival rate of DLBCL is only 63.9% with up to 40% of the patients often fail to respond or relapse following this regimen. For patients with relapsed or refractory DLBCL, prognosis is often unfavorable even with high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) 4,5.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-19
      DOI: 10.1016/j.clml.2022.08.006
       
  • Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review

    • Free pre-print version: Loading...

      Authors: Arpita Gandhi; Benjamin Andrick, Julianne Darling, Tuyet Truong, Jessie Signorelli Pharm
      Abstract: AML is a biologically and clinically heterogeneous disease that is associated with poor overall long-term survival. The expanding knowledge of genomic landscape in AML as well as advancements in molecular and chemical biology over the pathway in AML. After 40 years of stagnancy, the recent approval of numerous novel oral anti-leukemic agents for the treatment of AML has changed both the armamentarium of medications and treatment paradigms. These agents have unique clinical considerations in terms of administration, adverse effects, and monitoring parameters which may differ from clinician's historical expectations.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-19
      DOI: 10.1016/j.clml.2022.08.005
       
  • Belantamab in Combination with Dexamethasone in Patients with Triple-class
           Relapsed/Refractory Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Tahani Atieh; Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Susana Hajjar, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah
      Abstract: Triple-class relapsed/refractory multiple myeloma (RRMM) has a poor prognosis. This study analyzed the clinical outcomes of Belantamab mafadotin in combination with dexamethasone (Bd) in triple-class RRMM. We identified 35 patients with triple-class RRMM who received Bd at the University of Kansas from October 2019 to November 2021. The median age was 66 years (42-85) and the median prior lines of therapy was 5 (3-15). Nineteen (54%) patients had R-ISS stage III disease, 15 (43%) patients had high-risk cytogenetics, and 15 patients (43%) had extramedullary disease (EMD).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-15
      DOI: 10.1016/j.clml.2022.08.003
       
  • SOHO State of the Art Updates and Next Questions: Measurable Residual
           Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in
           2022 and Beyond

    • Free pre-print version: Loading...

      Authors: Simone E. Dekker; Jessica Leonard, Lori Muffly
      Abstract: Measurable residual disease (MRD) is an established component of acute lymphoblastic leukemia (ALL) management in both children and adults. Society guidelines and expert consensus documents include assessment of MRD as the standard of care following induction therapy, consolidation therapy, and at additional time points, depending on the treatment regimen administered. Further, the approval of blinatumomab for MRD+ B-ALL has advanced the concept of MRD response as a clinical endpoint in ALL. Although the utility of MRD in ALL has been well defined over the last decades, several questions remain.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-14
      DOI: 10.1016/j.clml.2022.08.004
       
  • Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple
           Myeloma

    • Free pre-print version: Loading...

      Authors: Abdel Rahem S. Yusuf; Hillary M. Heiling, Allison M. Deal, Christopher E. Jensen, Nicholas J. Mangieri, Kirsten A. Nyrop, Eben I. Lichtman, Samuel M. Rubinstein, Shakira J. Grant, William A. Wood, Sascha A. Tuchman, Zev M. Nakamura
      Abstract: With an incidence that has risen 126% globally since 1990, multiple myeloma (MM) is now the second most common hematologic cancer and the 14th most common neoplasm in the US.1 Functional limitations, including those related to housekeeping, handling finances, and community integration, are extraordinarily common in patients with MM.2,3 However, an often-overlooked consequence of MM and its treatments is cognitive dysfunction, often referred to as cancer-related cognitive impairment (CRCI).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-14
      DOI: 10.1016/j.clml.2022.08.002
       
  • Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections,
           and Antimicrobial Resistance in Newly Diagnosed AML Patients

    • Free pre-print version: Loading...

      Authors: Jessica Caro; Rafael Madero-Marroquin, Nicole Zubizarreta, Erin Moshier, Douglas Tremblay, Alex Coltoff, Guido Lancman, Risa Fuller, Meenakshi Rana, John Mascarenhas, Samantha E. Jacobs
      Abstract: Fluoroquinolone prophylaxis is recommended during induction chemotherapy for patients with acute myeloid leukemia (AML) to reduce risk of neutropenic fever and systemic bacterial infections. We evaluated the effectiveness of primary fluoroquinolone prophylaxis in an area with high fluoroquinolone resistance.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-07
      DOI: 10.1016/j.clml.2022.08.001
       
  • Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An
           Updated Review

    • Free pre-print version: Loading...

      Authors: Mubarak Al-Mansour
      Abstract: Mantle cell lymphoma (MCL) accounts for nearly 2-6% of all non-Hodgkin lymphoma (NHL) cases, with a steady incidence increase over the past few decades. Although many patients achieve an adequate response to the upfront treatment, the short duration of remission with rapid relapse is challenging during MCL management. In this regard, there is no consensus on the best treatment options for relapsed/refractory (R/R) disease, and the international guidelines demonstrate wide variations in the recommended approaches.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-02
      DOI: 10.1016/j.clml.2022.07.017
       
  • Characteristics and Outcomes of Alberta Lymphoma Patients with a History
           of Immunosuppressive therapy for Autoimmune Conditions

    • Free pre-print version: Loading...

      Authors: Kosha Kantharia; Carolyn Owen, Douglas Stewart, Patrick Yau, Sunita Ghosh, Deonne Dersch-Mills
      Abstract: Other iatrogenic immunosuppression associated lymphoproliferative disorders (Oii-LPD) is rare subset of lymphoma. There are limited published data on the clinical characteristics and outcomes of this patient population. The primary objective of this study was to describe the clinical characteristics and outcomes of Alberta patients diagnosed with lymphoma following immunosuppressive therapy for autoimmune conditions. Secondary objectives included describing the incidence of Oii-LPD, proportions of subtypes of lymphoma diagnosed and the nature of immunosuppressants used.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-02
      DOI: 10.1016/j.clml.2022.07.016
       
  • Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate
           Survival Analysis Using Individual Patient Data from Eight Multicenter
           Randomized Clinical Trials

    • Free pre-print version: Loading...

      Authors: Jesse G. Dixon; Çağlar Çağlayan, Dai Chihara, Tina Nielsen, Natalie Dimier, Jamie Zheng, Anna K. Wall, Gilles Salles, Franck Morschhauser, Robert Marcus, Michael Herold, Eva Kimby, Kristie A Blum, Michele Ghielmini, Qian Shi, Christopher R. Flowers
      Abstract: : This study identified independent contributions of baseline clinical factors to distinct outcomes for patients with FL following first-line therapy on a clinical trial. Similar analytical approaches are needed to increase understanding of factors that influence FL outcomes in other settings.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-02
      DOI: 10.1016/j.clml.2022.07.015
       
  • Treatment of Ph-Negative Acute Lymphoblastic Leukemia in Adolescents and
           Young Adults with an Affordable Outpatient Pediatric Regimen

    • Free pre-print version: Loading...

      Authors: Andrés Gómez-De León; Ana L. Varela-Constantino, Perla R. Colunga-Pedraza, Alexia Sánchez-Arteaga, Valeria García-Zárate, Anna Cecilia Rodríguez-Zúñiga, Nereida Méndez-Ramírez, Olga G. Cantú-Rodríguez, César H. Gutiérrez-Aguirre, Luz Tarín-Arzaga, Elías E. González-López, José Carlos Jaime-Pérez, David Gómez-Almaguer
      Abstract: B-cell acute lymphoblastic leukemia (B-ALL) is more common in adolescents and young adults (AYAs) of Hispanic ancestry. An increased incidence has been reported in this population in several countries in America, including Mexico, where B-ALL is more frequent than acute myeloid leukemia, with an increased risk of relapse and a higher prevalence of the Ph-like phenotype1-3. Outcomes of AYAs with B-ALL have improved with the chemotherapy regimens used in children4. Pediatric-inspired regimens use higher doses of non-myeloablative chemotherapy (dexamethasone, vinca alkaloids, and L-asparaginase) and more intensive central nervous system (CNS) prophylaxis5-7.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-01
      DOI: 10.1016/j.clml.2022.07.014
       
  • SOHO State of the Art & Next Questions: Treatment of Higher-Risk
           Myelodysplastic Syndromes

    • Free pre-print version: Loading...

      Authors: Brandon J. Aubrey; Andrew Brunner
      Abstract: Higher-risk myelodysplastic syndromes (MDS) carry a dismal prognosis with rapid disease progression, disease-related complications that impact quality of life, high risk of transformation to acute myeloid leukemia (AML), and poor long-term survival. Higher-risk disease is determined by a number of factors including the depth and type of cytopenias, percentage of myeloblasts occupying the bone marrow, cytogenetic abnormalities, and increasingly also by the presence of higher-risk molecular alterations.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-23
      DOI: 10.1016/j.clml.2022.07.012
       
  • SOHO State of the Art Updates and Next Questions Mechanisms of Resistance
           to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukaemia and Potential
           Future Therapeutic Directions

    • Free pre-print version: Loading...

      Authors: Rory Bennett; Ella Thompson, Constantine Tam
      Abstract: Chronic lymphocytic leukaemia (CLL) constitutively overexpresses B-cell lymphoma 2 (BCL2) with consequent dysregulation of intrinsic apoptosis leading to abnormal cellular survival. Therapeutic use of BCL2 inhibitors (BCL2i, e.g. venetoclax) in CLL, as both continuous monotherapy or in fixed duration combination, has translated scientific rationale into clinical benefit with significant rates of complete responses, including those without detectable minimal residual disease. Unlike with chemotherapy, response rates to venetoclax do not appear to be influenced by pre-existing chromosomal abnormalities or somatic mutations present, although the duration of response observed remains shorter for those with traditional higher risk genetic aberrations.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-22
      DOI: 10.1016/j.clml.2022.07.013
       
  • CyBorD-DARA in newly diagnosed transplant-eligible multiple myeloma:
           results from the 16-BCNI-001/CTRIAL-IE 16-02 study show high rates of MRD
           negativity at end of treatment

    • Free pre-print version: Loading...

      Authors: D Swan; R Henderson, C McEllistrim, S D Naicker, J Quinn, M R Cahill, V Mykytiv, E Lenihan, E Mulvaney, M Nolan, I Parker, A Natoni, K Lynch, A E Ryan, E Szegezdi, J Krawczyk, P Murphy, M O'Dwyer
      Abstract: The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-21
      DOI: 10.1016/j.clml.2022.07.011
       
  • Impact of chronic kidney disease and acute kidney injury on safety and
           outcomes of CAR T-cell therapy in lymphoma patients.

    • Free pre-print version: Loading...

      Authors: Gulrayz Ahmed; Bhavna Bhasin-Chhabra, Aniko Szabo, Nirav N. Shah, Walter Longo, Binod Dhakal, Saurabh Chhabra, Anita D'Souza, Timothy S. Fenske, Mehdi Hamadani
      Abstract: Anti CD19 chimeric antigen receptor modified T-cell (CAR-T) therapy is a standard option for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) patients with at least two prior lines of therapy. Currently, there are four commercially available CAR-T products for NHL patients that can provide durable responses in a subset of high risk lymphoma patients with generally manageable safety profile.1-4 However, the safety and efficacy of these products in patients with pre-existing chronic kidney disease (CKD) is less well established.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-18
      DOI: 10.1016/j.clml.2022.07.007
       
  • Real-world efficacy of 5-azacytidine as salvage chemotherapy for
           angioimmunoblastic T-cell lymphoma

    • Free pre-print version: Loading...

      Authors: Sang Eun Yoon; Junhun Cho, Yeon Jeong Kim, Seok Jin Kim, Won Seog Kim
      Abstract: : Based on specific epigenetic mutation in AITL such as TET2, DNMT3A, IDH2, and RHOA, hypomethylating agents are emerging as a promising treatment option for AITL.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-17
      DOI: 10.1016/j.clml.2022.07.009
       
  • Cost-effectiveness of PET directed versus combined modality therapy for
           early-stage favorable Hodgkin's lymphoma

    • Free pre-print version: Loading...

      Authors: Clayton P. Smith; Bethel Adefres, Eric M. Chang, Tina Q. Huang, Neil Parikh, Ann Raldow
      Abstract: The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation trials have assessed the impact of omitting radiation with the use of positron emission tomography (PET) and have suggested a detriment in progression free survival (PFS) for patients who do not receive radiation therapy (RT) but similar overall survival. The purpose of this study was to compare the cost-effectiveness of PET-directed therapy vs.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-17
      DOI: 10.1016/j.clml.2022.07.005
       
  • Hodgkin lymphoma on hemodialysis: a review of treatment and
           recommendations

    • Free pre-print version: Loading...

      Authors: Hajime Yasuda; Norio Komatsu, Jun Ando, Miki Ando
      Abstract: Chemotherapy for classical Hodgkin lymphoma (cHL) patients on hemodialysis (HD) is an extremely challenging situation because pharmacokinetic and pharmacodynamic studies of most chemotherapeutics are lacking for the HD patient, and the small amount of evidence available comes mostly from case reports and small case series. HD patients undergoing chemotherapy are at risk of overdose and toxicities because many drugs are significantly eliminated by the kidneys, and at the same time, are at risk of undertreatment because many drugs are removed by HD.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-17
      DOI: 10.1016/j.clml.2022.07.008
       
  • Clinical characteristics and management of patients with concomitant liver
           cirrhosis and lymphoma: A systematic review

    • Free pre-print version: Loading...

      Authors: Jelena Jelicic; Thomas Stauffer Larsen, Annette Dam Fialla, Zoran Bukumiric, Bosko Andjelic
      Abstract: Liver cirrhosis and malignancy represent significant public health issues due to their high incidence 1. As both diseases are quite common in the general population, there is a risk of simultaneously suffering liver cirrhosis and malignancy 2.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-17
      DOI: 10.1016/j.clml.2022.07.006
       
  • High dimensional immune profiling of smoldering multiple myeloma
           distinguishes distinct tumor microenvironments

    • Free pre-print version: Loading...

      Authors: Nicolas Fernandez; Deepak Perumal, Adeeb Rahman, Seunghee Kim-Schulze, Jen Yesil, Daniel Auclair, Homer Adams, Samir Parekh, Sacha Gnjatic, Hearn Jay Cho
      Abstract: Multiple myeloma (MM) is a malignancy of plasma cells that arises from premalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) and often progresses through an asymptomatic Smoldering (SMM) phase. Understanding the interactions between abnormal clonal plasma cells and the tumor microenvironment (TME) in the early disease states (MGUS, SMM) may inform risk assessment and therapy. We performed high dimensional immunologic analysis of bone marrow specimens from 73 subjects with SMM by mass cytometry and T cell receptor sequencing of CD138-depleted bone marrow (BM) mononuclear cells, and proteomics and seromic profiling of BM plasma.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-15
      DOI: 10.1016/j.clml.2022.07.001
       
  • Real-World Persistence and Time to Next Treatment with Ibrutinib in
           Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
           Including Patients at High Risk for Atrial Fibrillation or Stroke

    • Free pre-print version: Loading...

      Authors: Anna Narezkina; Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi
      Abstract: : Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-12
      DOI: 10.1016/j.clml.2022.07.004
       
  • Pediatric plasma cell neoplasms: a population-based study

    • Free pre-print version: Loading...

      Authors: Pierre Loap; Marguerite Vignon, Didier Bouscary, Youlia Kirova
      Abstract: Plasma cell neoplasms, corresponding to an excessive proliferation of mature plasma cells, have diverse morphological presentations: according to the International Lymphoma Epidemiology Consortium1, malignant plasma cell neoplasms can be divided into plasmacytoma (either solitary bone plasmacytoma (SBP) or solitary extraosseous plasmacytoma (SEP), depending on the localization), plasma cell myeloma (PCM) or plasma cell leukemia (PCL). PCM, defined by a>10% infiltration of plasma cells in the bone marrow, is the second most frequent hematologic malignancy and represents the overwhelming majority of malignant plasma cell neoplasms, with an age-standardized incidence estimated around 50 cases for 1,000,000 person-years2; its 5-year overall survival is 56%3.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-10
      DOI: 10.1016/j.clml.2022.07.003
       
  • Longitudinal real-world neuropathy and patient-reported outcomes with
           bortezomib and lenalidomide in newly diagnosed multiple myeloma

    • Free pre-print version: Loading...

      Authors: Ajay Major; Andrzej Jakubowiak, Benjamin Derman
      Abstract: Peripheral neuropathy is a common symptom experienced by patients with newly-diagnosed multiple myeloma, with up to 75% of patients experiencing treatment-emergent neuropathy during frontline treatment.1,2 Recognition and management of neuropathy can be challenging in patients with multiple myeloma, as up to 20% of patients have neuropathy at diagnosis due to their underlying plasma cell dyscrasias or associated amyloidosis prior to treatment initiation.1,3 Neuropathy is a major contributor to poor health-related quality of life (HRQoL) in patients with myeloma4,5 and is also a major cause of dose reduction or treatment discontinuation in the real-world setting.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-10
      DOI: 10.1016/j.clml.2022.07.002
       
  • Gemcitabine, cisplatin and dexamethasone as a salvage and mobilization
           chemotherapy before autologous stem cell transplantation is effective and
           safe outpatient regimen in relapsed and refractory Hodgkin lymphoma
           patients

    • Free pre-print version: Loading...

      Authors: Ayla Gokmen; Ugur Sahin, Ender Soydan, Zafer Gokgoz, Mevlude Kurdal Okcu, Ulku Ozan, Onder Arslan, Osman Ilhan, Muhit Ozcan
      Abstract: Second line salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the current standard treatment for eligible patients with relapsed and refractory (R/R) Hodgkin lymphoma (HL). Several salvage regimens have been used before ASCT. However the optimal salvage regimen is still unclear. We report outcome of patients with R/R HL treated with gemcitabine, cisplatin and dexamethasone (GDP) regimen before ASCT in this retrospective study aiming at evaluating efficacy, stem cell mobilization activity and safety of GDP in a real life setting.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-30
      DOI: 10.1016/j.clml.2022.06.015
       
  • R-CHOP vs DA-EPOCH-R for double-expressor lymphoma: A University of
           California Hematologic Malignancies Consortium retrospective analysis

    • Free pre-print version: Loading...

      Authors: Tamer Othman; Juan Penaloza, Shiliang Zhang, Claire E. Daniel, Daria Gaut, Caspian Oliai, Elizabeth A Brem, Abinav Baweja, Jane Ly, Jack Reid, Lauren Pinter-Brown, Matthew Lee, Haifaa Abdulhaq, Joseph Tuscano
      Abstract: : Managing double-expressor lymphomas (DEL) is challenging due to limited data and lack of standardized guidelines. We performed the largest analysis to date exploring R-CHOP vs DA-EPOCH-R in DEL. There was no difference in survival between the 2 regimens, although in patients
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-29
      DOI: 10.1016/j.clml.2022.06.013
       
  • Patterns of utilization and outcomes of Autologous Stem Cell
           Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed
           or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6
           rearrangements

    • Free pre-print version: Loading...

      Authors: Sean Patrick Bliven; Lauren Shea, Susan Bal, Gaurav Goyal, Amitkumar Mehta, Mayur Narkhede
      Abstract: We evaluated patients with Diffuse Large B-cell Lymphoma to describe treatment patterns in relapsed/refractory disease. We observed that higher proportion of patients with double/triple-hit lymphoma (DHL) received salvage intent chemotherapy yet fewer proceeded to autologous stem cell transplant (ASCT) with lower overall survival compared to non-DHL.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-28
      DOI: 10.1016/j.clml.2022.06.011
       
  • Up-front therapy with CHOP plus etoposide in Brazilian nodal PTCL
           patients: increased toxicity and no survival benefit compared to CHOP
           regimen – results of a real-life study from a middle-income country

    • Free pre-print version: Loading...

      Authors: Luís Alberto de Pádua Covas Lage; Cláudio Vinícius Brito, Guilherme Carneiro Barreto, Hebert Fabrício Culler, Cadiele Oliana Reichert, Débora Levy, Renata de Oliveira Costa, Maria Cláudia Nogueira Zerbini, Vanderson Rocha, Juliana Pereira
      Abstract: Peripheral T-cell lymphomas (PTCL) are an uncommon and aggressive group of neoplasms derived from mature or post-thymic T-cells. As natural killer (NK) cells share some immunophenotypic and functional properties with T-cells, these malignancies are considered together [1,2]. It represents 15% of all non-Hodgkin's lymphomas (NHL) with significant variations in different geographic regions and racial populations, with predominance in inter-tropical areas, particularly Central, South America and Southeast Asia, where it accounts for up to 20-25% of all lymphoid neoplasms [1,3,4].
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-28
      DOI: 10.1016/j.clml.2022.06.012
       
  • The impact of sequence of therapy for older patients with follicular
           lymphoma: SEER-Medicare analysis

    • Free pre-print version: Loading...

      Authors: Can Xie; Ruosha Li, Xuelin Huang, Dai Chihara, Christopher R. Flowers
      Abstract: One key clinical challenge remains in how to sequence treatments in follicular lymphoma (FL). The chemoimmunotherapy R-CHOP has been a standard treatment option for two decades. However, there are limited data to suggest in which line R-CHOP should be used for older patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-28
      DOI: 10.1016/j.clml.2022.06.014
       
  • Retrospective Analysis of the Efficacy and Tolerability of
           Gemcitabine-based Chemotherapy in Relapsed/Refractory Lymphoma Patients
           Not Eligible for Stem Cell Transplant

    • Free pre-print version: Loading...

      Authors: May Chiu; Samuel Hague, Anna Elinder-Camburn, Eileen Merriman, Henry Chan
      Abstract: Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients with RR lymphoma treated with gemcitabine, cisplatin or carboplatin and dexamethasone (GDP/GDCarboP) +/- rituximab regimen in our center.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-28
      DOI: 10.1016/j.clml.2022.06.010
       
  • Real-world outcomes of ruxolitinib in patients with myelofibrosis focusing
           on red blood cell transfusion: A multicenter study from the MPN Working
           Party of the Korean Society of Hematology

    • Free pre-print version: Loading...

      Authors: Eun Hee Jung; Junshik Hong, Sung-Yong Kim, Young Park, Young Jin Yuh, Yeung-Chul Mun, Won-Sik Lee, Sung-Kyu Park, Soo Mee Bang
      Abstract: Ruxolitinib is an established treatment for myelofibrosis (MF) that has demonstrated clinical benefit by reducing spleen size and debilitating MF-related symptoms. However, despite the efficacy of ruxolitinib, anemia remains a major adverse event that causes dose modification or discontinuation in real-world practice. Additionally, dependence on red blood cell (RBC) transfusion (TF) is common during treatment; therefore, we explored the outcome of ruxolitinib therapy with a primary focus on RBC TF.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-26
      DOI: 10.1016/j.clml.2022.06.008
       
  • Induction therapy and survival for acute myeloid leukemia in Hispanic
           adults from Puerto Rico

    • Free pre-print version: Loading...

      Authors: Maira A. Castaneda-Avila; Tonatiuh Suárez Ramos, Carlos R. Torres-Cintrón, Luis A. Cotto-Santana, Guillermo Tortolero-Luna, Karen J. Ortiz-Ortiz
      Abstract: We described the first-line therapy and survival of Hispanics from Puerto Rico with acute myeloid leukemia (AML). Age, risk, and comorbidities were associated with induction therapy type. Among patients who received intensive therapy, those of ≥60 years had a higher risk of death. The low survival and the disparities observed highlight the need to examine further new treatment options for older and comorbid patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-23
      DOI: 10.1016/j.clml.2022.06.007
       
  • Comparison of Three Doses of Cytarabine Consolidation for Intermediate-
           and Adverse-risk Acute Myeloid Leukemia: Real World Evidence from Thai
           Acute Myeloid Leukemia Registry

    • Free pre-print version: Loading...

      Authors: Chantiya Chanswangphuwana; Chantana Polprasert, Weerapat Owattanapanich, Smith Kungwankiattichai, Ekarat Rattarittamrong, Thanawat Rattanathammethee, Wasithep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chinadol Wanitpongpun, Chajchawan Nakhakes, Kannadit Prayongratana, Chantrapa Sriswasdi
      Abstract: Background: Intermediate or high doses of cytarabine (IDAC or HiDAC) were recommended as post-remission chemotherapy for acute myeloid leukemia (AML). This retrospective study investigated the real-world outcomes of three-different cytarabine doses from the multicenter Thai AML registry database.Methods: The intermediate- and adverse-risk AML patients (N = 258) who achieved complete remission and proceeded to single-agent cytarabine consolidation were enrolled.Results: The median relapse-free survival (RFS) using IDAC 1.5g/m2, high-dose cytarabine (HiDAC) 2g/m2 and HiDAC 3g/m2 were 12.6, 11.7 and 13 months, respectively.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-12
      DOI: 10.1016/j.clml.2022.06.005
       
  • Effect of age and socioeconomic factors in the utilization of chemotherapy
           in Acute Lymphoblastic Leukemia (ALL): A SEER database study of 16,196
           patients

    • Free pre-print version: Loading...

      Authors: Utsav Joshi; Anurag Adhikari, Uttam Bhetuwal, Adheesh Bhattarai, Vishakha Agrawal, Shristi Upadhyay Banskota, Prajwal Dhakal, Vijaya Raj Bhatt
      Abstract: : Use of chemotherapy in ALL patients was assessed in real-world setting. Using the SEER database, we analyzed data of 16,196 patients diagnosed with ALL from 2006 to 2016. Utilization of chemotherapy decreased with advancing age. Additionally, single or widowed status, lower educational status, and lack of insurance were associated with lower receipt of chemotherapy.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-11
      DOI: 10.1016/j.clml.2022.06.006
       
  • PD-1 Blockade after Avelumab in Relapsed/Refractory Classical Hodgkin
           Lymphoma

    • Free pre-print version: Loading...

      Authors: Swetha Kambhampati; Matthew G. Mei, James Godfrey, Tanya Siddiqi, Amandeep Salhotra, Robert Chen, Eileen Smith, Leslie L. Popplewell, Alex F. Herrera
      Abstract: Anti-PD-1 directed therapy is safe and effective in patients with relapsed/refractory (r/r) cHL and is currently being studied in the frontline setting. There are currently little data regarding the safety and efficacy of PD-1 blockade after prior PD-L1 blockade with agents such as avelumab.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-06
      DOI: 10.1016/j.clml.2022.06.004
       
  • “Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes from
           a Developing Country”

    • Free pre-print version: Loading...

      Authors: Dr. Kunal Jobanputra; Dr. Lingaraj Nayak, Dr. Hasmukh Jain, Dr. Tanuja Shet, Dr. Sridhar Epari, Dr. V.N. Avinash Bonda, Dr. Jayashree Thorat, Dr. Bhausaheb Bagal, Dr. Siddhartha Laskar, Dr. Venkatesh Rangarajan, Dr. Archi Agrawal, Dr. Sumeet Gujral, Dr. Nehal Khanna, Dr. Jayant Sastri Goda, Dr. Manju Sengar
      Abstract: Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in the elderly aims to achieve disease remission while minimizing treatment-related toxicities. The use of anthracycline in the elderly is associated with increased risk of cardiotoxicity and myelosuppression. Non-anthracycline-based regimens have commonly been used in patients with cardiac contraindications or anticipated severe toxicities to anthracyclines.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-06
      DOI: 10.1016/j.clml.2022.06.003
       
  • Treatment Options for Patients With Heavily Pretreated Relapsed and
           Refractory Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Meletios-Athanasios Dimopoulos; Paul Richardson, Sagar Lonial
      Abstract: Despite the increasing number of treatment options available for multiple myeloma (MM), relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily pretreated patients with relapsed and refractory MM, with a focus on the optimal management of patients with MM refractory to lenalidomide, bortezomib, and in some cases, daratumumab or an anti-CD38 monoclonal antibody.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-01-08
      DOI: 10.1016/j.clml.2022.01.005
       
  • Prophylaxis and Management of Secondary CNS Lymphoma

    • Free pre-print version: Loading...

      Authors: Jillian Simard; Mark Roschewski
      First page: 709
      Abstract: Secondary CNS lymphoma (SCNSL) is a rare but frequently fatal complication of systemic lymphoma. There is no standard treatment for SCNSL, and patients who develop SCNSL at diagnosis or after frontline therapy often receive highly intensive chemotherapy regimens that are inactive against primary chemorefractory disease and too toxic for older, frail patients to tolerate. Because the prognosis of SCNSL is so poor, management has historically emphasized prevention, but the current methods of CNS prophylaxis are not universally effective.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-06
      DOI: 10.1016/j.clml.2022.06.002
       
  • SOHO State of the Art Updates and Next Questions Novel Approaches to
           Pediatric T-cell ALL and T- Lymphoblastic Lymphoma

    • Free pre-print version: Loading...

      Authors: Ryan J Summers; David T Teachey
      First page: 718
      Abstract: While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Improved risk stratification and the incorporation of novel therapeutics have the potential to improve outcomes further in T-ALL/T-LL by limiting relapse risk and improving salvage rates for those with r/r disease. In this review we will discuss the challenges and new opportunities for improved risk stratification in T-ALL and T-LL.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-07-20
      DOI: 10.1016/j.clml.2022.07.010
       
  • Prognostic Impact of Adiposity in Hematological Malignancies: A Systematic
           Review and Meta-analysis

    • Free pre-print version: Loading...

      Authors: Gabriel FP Aleixo; Michael Sheu, Saied Mirzai, Navneet S Majhail
      First page: 726
      Abstract: It has been proposed that direct measurement of adiposity has a greater accuracy as a prognostic factor in various malignancies than anthropometric measures such as BMI. We evaluated the association of visceral and subcutaneous adiposity with outcomes in patients with hematological malignancies with a systematic review and meta-analysis.This systematic review included patients with hematological malignancies who had the analysis of overall mortality and progression-free survival according to their adiposity status.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-28
      DOI: 10.1016/j.clml.2022.05.008
       
  • Consolidative Autologous Stem Cell Transplantation vs Whole Brain
           Radiation in PCNSL; A Nationwide analysis

    • Free pre-print version: Loading...

      Authors: Yazan Samhouri; Moaath K. Mustafa Ali, Jennie Law, Cyrus Khan, Rodney Wegner, Seung Tae Lee, John Lister
      First page: 735
      Abstract: Background The best consolidation strategy after induction chemotherapy in Primary CNS Lymphoma (PCNSL) remains controversial. Our objective is to estimate the overall survival (OS) for autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) in the consolidation setting. We also sought to evaluate the factors affecting treatment selection
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-23
      DOI: 10.1016/j.clml.2022.05.007
       
  • Tumor infiltrating lymphocytes predict survival in solid organ transplant
           

    • Free pre-print version: Loading...

      Authors: Ryan J. Stubbins; Ryan Lam, James Zhu, Sunita Ghosh, Curtis Mabilangan, John Kuruvilla, Rashmi S Goswami, Raymond Lai, Jutta K Preiksaitis, Michael D Jain, Anthea C Peters
      First page: 744
      Abstract: Post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of lymphoid malignancies that arise from immunosuppression following a hematopoietic or solid organ transplantation (SOT).1, 2 Epstein-Barr virus (EBV) infection or reactivation in the context of depressed T-cell mediated immunity contributes to PTLD pathogenesis, although over half of adult PTLD is EBV negative.3 PTLDs are classified into non-destructive (ND-PTLD), polymorphic (P-PTLD), monomorphic (M-PTLD), and classical Hodgkin lymphoma (CHL-PTLD) PTLD.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-23
      DOI: 10.1016/j.clml.2022.05.006
       
  • Severity of cytokine release syndrome influences outcome after
           axicabtagene ciloleucel for large B cell lymphoma: Results from the US
           Lymphoma CAR-T Consortium

    • Free pre-print version: Loading...

      Authors: Miriam T. Jacobs; Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph McGuirk, Abhinav Deol, Alison Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C. Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
      First page: 753
      Abstract: Patients with relapsed or refractory large B cell lymphoma (R/R LBCL) can benefit from anti-CD19 chimeric antigen receptor (CAR) T cell therapies. Axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel and tisagenlecleucel are approved by the Food and Drug Administration (FDA) based on the ZUMA-1, JULIET and TRANSCEND clinical trials1-3. However, CAR T cell therapy is associated with significant side effects in the form of cytokine release syndrome (CRS) and neurotoxicity now termed immune cell associated encephalopathy syndrome (ICANS)4-6.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-23
      DOI: 10.1016/j.clml.2022.05.004
       
  • Real world adherence to and persistence with oral oncolytics in multiple
           myeloma: A systematic review and meta-analysis

    • Free pre-print version: Loading...

      Authors: Abdallah Y. Naser; Richard Ofori-Asenso, Safaa Al Awawdeh, Sami Qadus, Hassan Alwafi, Danny Liew
      First page: 760
      Abstract: Multiple myeloma (MM) is one of the most prevalent haematological malignancies globally, and is associated with substantial morbidity and mortality1. In 2020, there was an estimated 176,404 new cases of, and 117,077 deaths due to MM worldwide2. The incidence of MM has tended to be the highest in North America, Australia, New Zealand, and Europe3, with the median age of diagnosis being 66-70 years4.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-23
      DOI: 10.1016/j.clml.2022.05.003
       
  • CPX-351 yields similar response and survival outcome in younger and older
           patients with secondary acute myeloid leukemia

    • Free pre-print version: Loading...

      Authors: Dasom Lee; Akriti G Jain, Yehuda Deutsch, Jennifer Eatrides, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, Jeffrey Lancet, David Sallman, Chetasi Talati, Kendra Sweet
      First page: 774
      Abstract: : CPX-351 was approved by the FDA in 2017 as frontline induction chemotherapy for patients aged ≥18 years with newly diagnosed acute myeloid leukemia (AML) which includes myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leukemia (t-AML). The efficacy of CPX-351 among younger patients (aged
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-06-04
      DOI: 10.1016/j.clml.2022.06.001
       
  • Peripheral T-cell lymphoma, hemophagocytic lymphohistiocytosis and XIAP
           gene mutations: getting the treatment right!

    • Free pre-print version: Loading...

      Authors: Vinay Anand Guntiboina; Vivek S Radhakrishnan, Jeevan Kumar, Saurabh J Bhave, Sushant Vinarkar, Jayanta Das, Indu Arun, Deepak Kumar Mishra, Mammen Chandy, Reena Nair
      First page: 780
      Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a distinct hematological condition characterized by unregulated activation of the immune system, which may be genetically inherited or secondary to an underlying pathology. In this case report, we describe a 39-year-old patient with a history of persistent fever, weakness, progressive jaundice and bicytopenia who was hospitalized in the critical care unit. Evaluation included a lymph node biopsy, whole body imaging with a PET scan and a bone marrow examination, which resulted in a diagnosis of peripheral t-cell lymphoma (PTCL) along with bone marrow hemophagocytosis.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-05-23
      DOI: 10.1016/j.clml.2022.05.005
       
  • Corrigendum to “P-196: Isatuximab Plus Carfilzomib and Dexamethasone in
           Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas:
           IKEMA Subgroup Analysis, Clinical Lymphoma Myeloma and Leukemia” [Vol21,
           Sup 2, Oct 2021, Pages S145-S146]

    • Free pre-print version: Loading...

      First page: 785
      Abstract: Roman Hájek1, Tomas Jelinek2, Philippe Moreau3, Thomas Martin4 Luděk Pour5 Gábor Mikala6 Argiris Symeonidis7, Sara Bringhen8, Andreea Rawlings9, Marie-Laure Risse10, Helgi van de Velde9 Ivan Špička11
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2022)
      PubDate: 2022-08-20
      DOI: 10.1016/j.clml.2022.06.009
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.201.97.26
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-